Community drug distributors for mass drug administration in neglected tropical disease programmes: systematic review and analysis of policy documents.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
Dec 2019
Historique:
entrez: 31 10 2019
pubmed: 31 10 2019
medline: 28 11 2019
Statut: ppublish

Résumé

Mass drug administration (MDA) programmes for neglected tropical diseases (NTDs) depend on voluntary community drug distributors (CDDs) to deliver drugs, and these volunteer schemes need regular training and supervision. NTD policy now includes integration of multiple disease programmes, but we are unsure if there is clarity in what is currently expected of CDDs and how they are managed. We therefore analysed World Health Organization (WHO) policy, strategy and implementation guidance, and select national NTD programme implementation plans. Included are a) WHO global and WHO-Regional Office for Africa guidelines, strategies, operational manuals and meeting reports published between January 2007 to February 2018 that included policy and plans for CDDs; and b) national NTD programme master plans for Cameroon, Ghana, Liberia and Nigeria. For both review components, we examined the CDD responsibilities through a framework developed iteratively against the documents and prepared a narrative synthesis. Twenty WHO policy documents met the inclusion criteria. In the twelve global and eight regional documents, the CDD role was not explicitly or comprehensively defined. Three documents mentioned CDDs will distribute drugs; some mentioned health promotion, data handling and engagement in clinical care. Four WHO documents noted a need for CDD training or management, eight detailed some aspect of this, and one regional document provided a comprehensive overview. In the national plans, additional responsibilities included case management in two countries and transmission control in two countries. Every plan included training and supervision, but this was not always explicit, and details of the purpose and frequency varied. In all national plans, CDD motivation was identified as a challenge but not comprehensively addressed, although one document mentioned provision of bicycles. WHO and national policies and plans assume CDDs will implement NTD programmes. However, there is almost no clear delineation of responsibilities, nor is there up-to-date practical guidance to guide managers. This ambiguity, in relation to the lack of explicit policies or programmatic guidance, probably impairs the effectiveness of NTD programmes.

Sections du résumé

BACKGROUND BACKGROUND
Mass drug administration (MDA) programmes for neglected tropical diseases (NTDs) depend on voluntary community drug distributors (CDDs) to deliver drugs, and these volunteer schemes need regular training and supervision. NTD policy now includes integration of multiple disease programmes, but we are unsure if there is clarity in what is currently expected of CDDs and how they are managed. We therefore analysed World Health Organization (WHO) policy, strategy and implementation guidance, and select national NTD programme implementation plans.
METHODS METHODS
Included are a) WHO global and WHO-Regional Office for Africa guidelines, strategies, operational manuals and meeting reports published between January 2007 to February 2018 that included policy and plans for CDDs; and b) national NTD programme master plans for Cameroon, Ghana, Liberia and Nigeria. For both review components, we examined the CDD responsibilities through a framework developed iteratively against the documents and prepared a narrative synthesis.
RESULTS RESULTS
Twenty WHO policy documents met the inclusion criteria. In the twelve global and eight regional documents, the CDD role was not explicitly or comprehensively defined. Three documents mentioned CDDs will distribute drugs; some mentioned health promotion, data handling and engagement in clinical care. Four WHO documents noted a need for CDD training or management, eight detailed some aspect of this, and one regional document provided a comprehensive overview. In the national plans, additional responsibilities included case management in two countries and transmission control in two countries. Every plan included training and supervision, but this was not always explicit, and details of the purpose and frequency varied. In all national plans, CDD motivation was identified as a challenge but not comprehensively addressed, although one document mentioned provision of bicycles.
CONCLUSIONS CONCLUSIONS
WHO and national policies and plans assume CDDs will implement NTD programmes. However, there is almost no clear delineation of responsibilities, nor is there up-to-date practical guidance to guide managers. This ambiguity, in relation to the lack of explicit policies or programmatic guidance, probably impairs the effectiveness of NTD programmes.

Identifiants

pubmed: 31662849
doi: 10.7189/jogh.09.020414
pii: jogh-09-020414
pmc: PMC6790237
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

020414

Informations de copyright

Copyright © 2019 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Competing interests: CM, LD and RT are all funded by DFID-funded research project called COUNTDOWN, which aims to improve MDA programmes for NTDs. PG is co-ordinating editor of the Cochrane Infectious Diseases Group that carries out systematic reviews of the effects of interventions in NTDs. This analysis is an output of the ‘evidence synthesis’ theme of the project. The views expressed in the submitted article are the authors and not an official position of the funder or the COUNTDOWN consortium or DFID. All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author), and declare no further conflicts of interest.

Références

PLoS Negl Trop Dis. 2008 Apr 30;2(4):e230
pubmed: 18446206
PLoS Negl Trop Dis. 2016 Aug 16;10(8):e0004905
pubmed: 27529622
J Nurs Scholarsh. 2015 Jan;47(1):96-104
pubmed: 25565278
Am J Trop Med Hyg. 2002 Sep;67(3):266-72
pubmed: 12408665
Lancet. 2016 Oct 8;388(10053):1603-1658
pubmed: 27733283
Am J Trop Med Hyg. 2012 Dec;87(6):1065-72
pubmed: 23091190
PLoS Med. 2005 Nov;2(11):e336
pubmed: 16212468
PLoS Negl Trop Dis. 2017 Dec 6;11(12):e0006065
pubmed: 29211746
Lancet. 2009 May 2;373(9674):1570-5
pubmed: 19410718
Parasit Vectors. 2016 Jun 16;9(1):345
pubmed: 27305942
PLoS Negl Trop Dis. 2010 Jun 29;4(6):e755
pubmed: 20614017
Trends Parasitol. 2012 May;28(5):195-201
pubmed: 22475459
Trends Parasitol. 2006 Jul;22(7):285-91
pubmed: 16730230
Health Res Policy Syst. 2011 Jan 06;9:3
pubmed: 21211001
Hum Resour Health. 2017 Sep 2;15(1):59
pubmed: 28865471
Am J Trop Med Hyg. 2012 Mar;86(3):508-513
pubmed: 22403327
PLoS One. 2012;7(11):e48395
pubmed: 23185256
SAGE Open Med. 2015 Jul 08;3:2050312115594083
pubmed: 26770791
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004015
pubmed: 20238326
Ann Trop Med Parasitol. 2002 Mar;96 Suppl 1:S93-104
pubmed: 12081254
BMC Med. 2019 Mar 28;17(1):69
pubmed: 30917824
Trends Parasitol. 2007 Oct;23(10):485-93
pubmed: 17826335
World Health Organ Tech Rep Ser. 2002;912:i-vi, 1-57, back cover
pubmed: 12592987
Trends Parasitol. 2006 Jul;22(7):313-21
pubmed: 16713738
J Biosoc Sci. 2017 Jul;49(4):447-462
pubmed: 27470198
Nat Commun. 2017 Dec 5;8(1):1929
pubmed: 29208898

Auteurs

Cara L Macfarlane (CL)

Centre for Evidence Synthesis in Global Health, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Laura Dean (L)

Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK.

Rachael Thomson (R)

Department for Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, UK.

Paul Garner (P)

Centre for Evidence Synthesis in Global Health, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH